<DOC>
	<DOCNO>NCT02154334</DOCNO>
	<brief_summary>The purpose study evaluate effect allergic rhinitis ( group symptoms affect nose ) co-administration mometasone oxymetazoline pharmacokinetics ( explores body drug ) , safety , tolerability intranasal ( administer nose ) esketamine .</brief_summary>
	<brief_title>Study Assess Effects Allergic Rhinitis Co-administration Mometasone Oxymetazoline Pharmacokinetics , Safety , Tolerability Intranasal Esketamine</brief_title>
	<detailed_description>This Phase 1 , single-center , open -label ( people know identity intervention ) study intranasal esketamine two cohort : Cohort 1 healthy participant assign fixed treatment sequence Cohort 2 participant nasal rhinitis randomize 1 2 treatment sequence . For participant , study comprise 3 phase : Screening phase ( 21 day ) , Open Label Treatment phase ( include 2 treatment period ; Period 1 Period 2 ) Follow-up phase ( 10 +/-2 day last dose esketamine ) . Total study duration participant Cohort 1 52 day include Screening phase , Period 1 ( 3 day ) participant self-administer 56 milligram ( mg ) intranasal dose esketamine solution Day 1 Period 2 ( 16 day ) participant self-administer 200 microgram ( mcg ) intranasal mometasone suspension Day 1 ( begin immediately follow 30 hour pharmacokinetic sample Period 1 ) Day 15 , 200 mcg intranasal mometasone suspension prior 56 mg dose intranasal esketamine solution Day 16 follow-up phase . Total study duration participant Cohort 2 44 day include Screening phase , Period 1 Period 2 3 day washout period 5 10 day in-between esketamine dosing , follow-up phase . Cohort 2 participant randomly assign either treatment Sequence 1 2 , wherein Sequence 1 comprise 56 mg intranasal dose esketamine solution alone period 1 follow period 2 comprises pretreatment oxymetazoline 0.05 percent ( % ) weight volume ( w/v ) solution 1 hour administration 56 mg intranasal dose esketamine solution . Sequence 2 comprises pretreatment oxymetazoline 0.05 % w/v solution 1 hour administration 56 mg intranasal dose esketamine solution Period 1 follow period 2 comprises 56 mg intranasal dose esketamine solution alone . Blood sample collect evaluation pharmacokinetic parameter intranasal esketamine healthy participant participant allergic rhinitis . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>Female participant must postmenopausal ( spontaneous menses least 2 year ) , surgically sterile , abstinent ( abstinence acceptable mean birth control already establish participant 's usual preferred lifestyle ) , , sexually active , practice effective method birth control ( example , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study Body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) ( inclusive ) , body weight less 50 kilogram ( kg ) Systolic blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) ( inclusive ) diastolic blood pressure 90 mmHg Comfortable selfadministration intranasal medication able follow instruction provide A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function For Cohort 2 , participant history allergic rhinitis positive prick test grass pollen screen For Cohort 2 , participant must Total Nasal Symptoms Score ( TNSS ) great equal ( &gt; = ) 6 nasal congestion score &gt; =2 ( minimum `` moderate rhinitis '' ) least one occasion participant ECC screen Current significant psychiatric ( mental disorder ) disorder include limit psychotic ( person exhibit mental illness ) , bipolar , major depressive anxiety disorder Clinically significant medical illness include ( limited ) cardiac arrhythmia ( irregular heart beat ) cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia [ disorder blood ] ) , lipid abnormality , significant pulmonary ( lung ) disease , include bronchospastic respiratory disease , diabetes mellitus ( disorder decrease insulin body body 's insulin effective , result high blood sugar , increase thirst urine , many side effect ) , renal hepatic insufficiency , thyroid disease , neurologic disease , infection , hypertension vascular disorder , kidney urinary tract disturbance , sleep apnea ( breathe problem sleep ) , myasthenia gravis ( disorder cause muscle get tired quickly ) , illness Investigator considers exclude participant could interfere interpretation study result Use prescription nonprescription medication , within 14 day first schedule dose study drug Anatomical medical condition may delay delivery absorption study medication ( example . undergone facial reconstruction , structural functional abnormality nose upper airway ; obstruction mucosal lesion [ visible local abnormality tissue skin ] nostril nasal passage ; undergone sinus [ depression cavity form bend curve ] surgery previous 2 year ; sign symptoms upper respiratory infection , rhinitis [ Cohort 1 ] , active allergy [ Cohort 1 ] , history frequent sinus infection complication ) Has abnormal deviate nasal septum ( inner wall separate two side nose one side ) 1 follow symptom : blockage 1 nostril , nasal congestion ( especially 1 side ) , frequent nosebleed , frequent sinus infection , noisy breathe sleep , facial pain , headache , postnasal drip</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Mometasone</keyword>
	<keyword>Oxymetazoline</keyword>
	<keyword>Phase 1</keyword>
</DOC>